Home

Rallybio Corporation - Common Stock (RLYB)

0.8765
0.00 (0.00%)

Rallybio Corporation is a biotechnology company focused on discovering and developing innovative therapies for rare and life-threatening diseases

The company specializes in creating breakthrough treatments that target the underlying causes of these conditions, aiming to significantly improve patient outcomes. Rallybio's research and development efforts are centered around advancing its robust pipeline of candidates designed to address critical unmet medical needs within the rare disease community. Through strategic partnerships and a commitment to scientific excellence, Rallybio is positioned to make a meaningful impact on patients' lives.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close0.8765
Open-
Bid0.8708
Ask0.9100
Day's RangeN/A - N/A
52 Week Range0.8410 - 3.460
Volume17
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume51,658

News & Press Releases

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today highlighted its 2024 accomplishments and announced its anticipated key milestones for 2025.
By Rallybio Corporation · Via Business Wire · January 10, 2025
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7–10, 2024 in San Diego, California.
By Rallybio Corporation · Via Business Wire · December 10, 2024
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced results of new biomarker characterization analyses and data from the recently completed manufacturing process enhancements for RLYB116, the Company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. Based on this recently completed work, Rallybio believes that RLYB116 has the potential to be a best-in-class C5 inhibitor and intends to initiate a confirmatory clinical pharmacokinetic/pharmacodynamic (PK/PD) study in the second quarter of 2025.
By Rallybio Corporation · Via Business Wire · December 2, 2024
RLYB Stock Earnings: Rallybio Beats EPS for Q1 2024investorplace.com
RLYB stock results show that Rallybio beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 9, 2024
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, “Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal Antibody,” in a special pregnancy themed issue of Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology.
By Rallybio Corporation · Via Business Wire · November 27, 2024
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET in Coral Gables, FL.
By Rallybio Corporation · Via Business Wire · November 26, 2024
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. The webcast will take place on Monday, December 2 at 8:30 AM Eastern Time and will review recent manufacturing process enhancements, biomarker characterization analyses, and the Company’s future plans for the program.
By Rallybio Corporation · Via Business Wire · November 25, 2024
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Screening is now underway to identify the first (sentinel) pregnant woman for enrollment in the Phase 2 trial.
By Rallybio Corporation · Via Business Wire · November 21, 2024
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported third quarter financial results for the period ended September 30, 2024, and provided an update on recent company developments.
By Rallybio Corporation · Via Business Wire · November 7, 2024
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the approval of its clinical trial applications (CTAs) for a Phase 2 clinical trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). With these approvals from the European Medicines Agency (EMA) and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), Rallybio will begin to activate Phase 2 clinical sites and expects to initiate screening of participants in the fourth quarter of 2024.
By Rallybio Corporation · Via Business Wire · October 29, 2024
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that nonclinical data demonstrating ENPP1 inhibition as a therapeutic approach for the treatment of patients with hypophosphatasia (HPP) was presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. ASBMR is being held September 27 – 30, 2024 in Toronto, Canada.
By Rallybio Corporation · Via Business Wire · September 30, 2024
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia (FNAIT)-impacted pregnancy will be presented at the American Society of Human Genetics (ASHG) 2024 Annual Meeting to be held November 5 – 9, 2024 in Denver, CO.
By Rallybio Corporation · Via Business Wire · September 23, 2024
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia (FNAIT)-impacted pregnancy will be presented at the NORD Rare Diseases & Orphan Products Breakthrough Summit to be held October 20 – 22, 2024 in Washington DC.
By Rallybio Corporation · Via Business Wire · September 10, 2024
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that Fierce Life Sciences and Fierce Healthcare has named Rallybio an Innovation Honoree as part of the 2024 Fierce 50 list. The Fierce 50 showcases 50 individuals and companies driving advancements in medicine, fostering innovation, and shaping the future of biopharma and healthcare.
By Rallybio Corporation · Via Business Wire · September 9, 2024
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that data from the Phase 1 proof-of-concept study of RLYB212, a novel monoclonal anti-HPA-1a antibody in development for the prevention of maternal alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT), were published in Thrombosis and Haemostasis. Top-line results from this study were previously presented at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) in 2023.
By Rallybio Corporation · Via Business Wire · August 29, 2024
Rallybio to Present at Upcoming Investor Conferences
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced its participation in the following upcoming investor conferences:
By Rallybio Corporation · Via Business Wire · August 27, 2024
RLYB Stock Earnings: Rallybio Misses EPS for Q2 2024investorplace.com
RLYB stock results show that Rallybio missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 8, 2024
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported second quarter financial results for the period ended June 30, 2024, and provided an update on recent company developments.
By Rallybio Corporation · Via Business Wire · August 8, 2024
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Jonathan Lieber, Chief Financial Officer of Rallybio, will present a corporate overview at the 2024 Jones Healthcare Seaside Summit on July 15, 2024 at 8:00 a.m. PT (11:00 a.m. ET) in Encinitas, CA.
By Rallybio Corporation · Via Business Wire · July 9, 2024
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported topline results from an epidemiological analysis of large genomic datasets evaluating the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk in diverse ancestries. Data from this analysis confirmed Caucasian populations as having the greatest proportion of women with the genetic markers for higher FNAIT risk (HPA-1a negative, HLA-DRB3*01:01 positive). Additionally, data from this analysis provides, for the first time, robust evidence quantifying the proportion of women in non-Caucasian ancestries that carry the genetic markers for higher FNAIT risk.
By Rallybio Corporation · Via Business Wire · June 17, 2024
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · June 6, 2024
3 Sorry Biotech Stocks to Sell in May While You Still Caninvestorplace.com
Morgan Stanley's bullish outlook highlights the need for strategic trimming of underperforming biotech stocks to sell.
Via InvestorPlace · May 31, 2024
3 Biotech Stocks to Sell in May Before They Crash & Burninvestorplace.com
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.
Via InvestorPlace · May 10, 2024
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2024 and provided an update on recent company developments.
By Rallybio Corporation · Via Business Wire · May 9, 2024
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024 at 11:30 a.m. ET in New York, NY.
By Rallybio Corporation · Via Business Wire · May 7, 2024